

Disclosure

All authors are employees of AbbVie and may own AbbVie stock. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

For Research Use Only. Not for use in diagnostic procedures.


abbvie


Application of Targeted Mass Spectrometry Imaging in the Pharmaceutical Industry

Andrew Bowman*, Junhai Yang,
Alena Joignant, Chris Good, David
Wagner, and Nari Talaty

AbbVie QTAS

Drug Metabolism and Disposition





Matrices
(Blood, Urine, Feces etc.)

LC-MS
(Matrices) Homogenates

Tissues
(Liver, Kidney, Brain, Eye, Tumor)



Distribution
Tissue Imaging
(MS, Optical, PET, etc)

Pharmacokinetics
Fate of a Drug

Pharmacodynamics
Effect of Drug

Pharmaceutics
Science of dosage form design


Pharmacology
Drug Action



Quantitative Biodistribution of Drugs


Tissue Imaging

- Imaging provides distribution across tissue
- Detect changes in morphology and translate to disease state
- Follow physiological changes in tissue



- Project teams need **quantitative** data
- If not quantitative, less valuable
- Pharmacology is a quantitative science

Mass Spectrometry Imaging



- Drugs, metabolites, and endogenous compounds are desorbed from **discrete spots** in an ordered array.

Everything on the Tissues:
Each **pixel** is a **full mass scan** for **all Drug, Metabolites, Endogenous compounds, Biomarkers** compounds ionized from the tissue, spot.

- The abundances of individual ions are **independently plotted** per pixel to **visualize** their distribution as ion images.
- Each ion has its **own** image.
- **Compare** compound distribution to histology results
- **Correlate** with H&E, fluorescence, MRI, any other imaging technology

Utility of Distribution in Pharmaceutical Research

Molecular Histology

MSI combines **high sensitivity and accuracy** of MS for identification, with **histology-like information** (spatial distribution) within tissue sections

Target Identification


Lead Generation Optimization

Candidate Selection and Development

Pre-clinical Development


Clinical Development

Target Engagement




- Reaching target
- Target Occupancy
- Time at target
- Efficacy
- Compound selection
- Formula selection

Biomarker Identification




- Markers of efficacy
- Explore signaling mechanisms
- Understand pathology to discover therapeutic targets

Multi-modal Integration




- Relate morphology to distribution
- Hepatotoxicity
- CNS penetration
- Tumor distribution
- PK/PD relationship

Toxicity Support




- Safety
- ID molecules responsible for toxicity

Tissue Distribution



- Target distribution
- Metabolism
- Clearance
- Tissue PK/PD
- Exposure studies
- Drug accumulation

Clinical



- PK/PD in human tissues
- Dose response
- Efficacy
- Target

Characteristics of MS Imaging

Advantages

- Spatially resolved molecular information across tissue
- Label-free analysis
- MSI can detect a wide range of molecules with good sensitivity and specificity
- Simultaneously detect and analyze thousands compounds
- Combined with (MS/MS), can provide structural information

Disadvantages

- Generates large, complex datasets that require advanced analysis techniques.
- Requires meticulous sample preparation, which can affect data quality
- Quantification challenges
- Instrumentation cost and complexity

Mass spectrometry imaging has proven critical in the pharmaceutical industry, but its broad utility requires addressing key challenges of sensitivity and cost

Can be facilitated by Targeted Imaging

Untargeted vs Targeted MSI

Untargeted Mass Spectrometry Imaging

Pros:

- **Spatial mapping** broad range of molecules, without prior knowledge
- Ideal for exploratory studies (new or unexpected compounds)

Cons:

- Generates large, complex datasets
- Generally semi-quantitative
- **Lower Sensitivity**

Applications: Commonly used in studies focused on identifying/discovering molecules across the tissues: **understanding of** disease signaling mechanisms, biomarker **discovery, metabolism** across tissues.

Targeted Mass Spectrometry Imaging

Pros:

- **High Sensitivity and Specificity**
- Allows for more accurate quantification.
- **Simplified Data Analysis**

Cons:

- Only predetermined molecules are analyzed
- **Lack of Exploratory Potential**

Applications: Best suited for applications requiring detailed investigation of known compounds, target engagement, and monitoring specific drug/metabolite distributions or biomarkers in tissues.

Currently, a **targeted MALDI platform is NOT commercially available** that combines high spatial resolution, highly robust workflow, and user-friendly experience

Collaboration with Agilent for Targeted Imaging using MALDI

Focus on improving sensitivity

Drug Efficacy (Target Engagement)

Biomarker monitoring

Tissue PK/PD

Drug Accumulation

Compounds

Low dosed compounds

ADC moieties (payload)

Quantitation

Agilent


- 6495D state of the art QqQ
- Provide strategies to obtain best sensitivity and data quality
- Provide support with data processing
- Provide support for hardware modifications

Mass Tech

- Provide AP-MALDI Source
- Ability to modify inlet system

AbbVie

- Provide real world samples and applications
- Determine scientific gaps and robustness
- Provide ideas for enhancing technology



Triple Quadrupole MS Imaging




Agilent 6495D



MassTech AP-MALDI UHR


QqQ Schematic



- ✓ Significant increase in sensitivity
- ✓ Targeted imaging (only looking for known molecules)
- ✓ Useful for low tissue concentrations

Sensitivity of Targeted Imaging vs. Scanning Mode

Visualizing low-dose drug compound





timsTOF Flex
Untargeted
Dosed


QqQ
Targeted
Vehicle Control

QqQ
Targeted
Dosed

Running the MassTech source: Adjusting Frequency and Accumulation Time for an Endogenous Lipid (PC 34:1)



Running the MassTech source: Adjusting Frequency and Accumulation Time for a Spotted Analyte (Reserpine)



Conclusions and Future Work

- **Targeted MS imaging** is increasingly important in supporting drug discovery, development, and clinical trials within the pharmaceutical industry.
- There is a **growing need** for a high-throughput targeted MS imaging platform that offers high spatial resolution for analyzing drug compounds, metabolites, disease markers, and treatment markers.
- Initial experiments demonstrate the **significant potential of combining AP-MALDI with QqQ** to serve as a targeted MS imaging platform and address existing gaps.
- Continue to develop QqQ methods and data analysis pipelines (file conversion) for more compounds and applications
- Determine sensitivity increases across broad compound classes
- Implement rapid MRM scanning workflow

Acknowledgements

We would like to thank the following Scientists from Agilent for their assistance with the installation, training, and troubleshooting involved in setting up the target MS imaging application for this platform:

Xi Qiu – Applications Chemist in Little Falls Center of Excellence

Jon Osborn – MS Product Specialist

John Sausen – Director of Strategic Initiatives - Mass Spectrometry

Sheher Mohsin – Applications Chemist

Fernando Tobias – Bioanalytical - Mass Spectrometry

We extend our gratitude to Venkat Panchagnula, Konstantin Novoselov from MassTech Inc for the training and troubleshooting.